Loading...
Loading...
Oculus Innovative Sciences, Inc.
OCLS a healthcare company that
designs, produces and markets innovative, safe and effective anti-infective
products and medical devices while also developing multiple drug candidates,
today announced that a pending reclassification of the company's CE Mark for
the European formulation Dermacyn(tm) Wound Care for the European market is
expected by year's end. The reclassification is under the review of the British
Standards Institution (BSI), which is the world's largest certification body,
and the Medicines and Healthcare products Regulatory Agency (MHRA) in the
United Kingdom. Reclassified as a class III medical device, the newest
indication would include 'possible local antimicrobial effect in the wound
bed.'
'We are pleased with the expanded label indication as it will help increase
sales for our existing sales partners in Europe and secondly, increases our
chances of licensing our anti-infective drug product to prospective European
partners focused on the surgical suite,' said Hoji Alimi, Oculus founder and
CEO. 'As evidenced by our effective collaborative efforts with partners in the
United States and Mexico, our partnership strategy has facilitated a
sustainable rapid sales ramp while minimizing expenses since our partners
underwrite the costs associated with marketing and sales.'
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in